358 related articles for article (PubMed ID: 17708365)
1. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
[TBL] [Abstract][Full Text] [Related]
2. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
3. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
4. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
[TBL] [Abstract][Full Text] [Related]
6. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
7. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
11. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases.
Sirvent JJ; Salvadó MT; Santafé M; Martínez S; Brunet J; Alvaro T; Palacios J
Histol Histopathol; 1995 Jul; 10(3):531-9. PubMed ID: 7579801
[TBL] [Abstract][Full Text] [Related]
12. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
[TBL] [Abstract][Full Text] [Related]
13. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
[TBL] [Abstract][Full Text] [Related]
14. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
[TBL] [Abstract][Full Text] [Related]
15. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
16. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
Arafah M
Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
[TBL] [Abstract][Full Text] [Related]
17. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
[TBL] [Abstract][Full Text] [Related]
18. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
[TBL] [Abstract][Full Text] [Related]
19. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
20. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.
DiGiovanna MP; Chu P; Davison TL; Howe CL; Carter D; Claus EB; Stern DF
Cancer Res; 2002 Nov; 62(22):6667-73. PubMed ID: 12438265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
